Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin

Bethany L. Johnson-Kerner, Faizzan S. Ahmad, Alejandro Garcia Diaz, John Palmer Greene, Steven J. Gray, Richard Jude Samulski, Wendy K. Chung, Rudy Van Coster, Paul Maertens, Scott A. Noggle, Christopher E. Henderson, Hynek Wichterle

    Research output: Contribution to journalArticle

    14 Citations (Scopus)

    Abstract

    Giant axonal neuropathy (GAN) is a progressive neurodegenerative disease caused by autosomal recessive mutations in the GAN gene resulting in a loss of a ubiquitously expressed protein, gigaxonin. Gene replacement therapy is a promising strategy for treatment of the disease; however, the effectiveness and safety of gigaxonin reintroduction have not been tested in human GAN nerve cells. Herewe report the derivation of induced pluripotent stem cells (iPSCs) from three GAN patients with different GAN mutations. Motor neurons differentiated from GAN iPSCs exhibit accumulation of neurofilament (NF-L) and peripherin (PRPH) protein and formation of PRPH aggregates, the key pathological phenotypes observed in patients. Introduction of gigaxonin either using a lentiviral vector or as a stable transgene resulted in normalization of NEFL and PRPH levels in GAN neurons and disappearance of PRPH aggregates. Importantly, overexpression of gigaxonin had no adverse effect on survival of GAN neurons, supporting the feasibility of gene replacement therapy. Our findings demonstrate that GAN iPSCs provide a novel model for studying human GAN neuropathologies and for the development and testing of new therapies in relevant cell types.

    Original languageEnglish
    Pages (from-to)1420-1431
    Number of pages12
    JournalHuman Molecular Genetics
    Volume24
    Issue number5
    DOIs
    Publication statusPublished - 1 Mar 2015

    Fingerprint

    Giant Axonal Neuropathy
    Intermediate Filament Proteins
    Induced Pluripotent Stem Cells
    Motor Neurons
    Peripherins
    Neurons
    Genetic Therapy
    Neurofilament Proteins
    Mutation
    Transgenes
    Neurodegenerative Diseases

    ASJC Scopus subject areas

    • Genetics
    • Genetics(clinical)
    • Molecular Biology

    Cite this

    Johnson-Kerner, B. L., Ahmad, F. S., Diaz, A. G., Greene, J. P., Gray, S. J., Samulski, R. J., ... Wichterle, H. (2015). Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin. Human Molecular Genetics, 24(5), 1420-1431. https://doi.org/10.1093/hmg/ddu556

    Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin. / Johnson-Kerner, Bethany L.; Ahmad, Faizzan S.; Diaz, Alejandro Garcia; Greene, John Palmer; Gray, Steven J.; Samulski, Richard Jude; Chung, Wendy K.; Van Coster, Rudy; Maertens, Paul; Noggle, Scott A.; Henderson, Christopher E.; Wichterle, Hynek.

    In: Human Molecular Genetics, Vol. 24, No. 5, 01.03.2015, p. 1420-1431.

    Research output: Contribution to journalArticle

    Johnson-Kerner, BL, Ahmad, FS, Diaz, AG, Greene, JP, Gray, SJ, Samulski, RJ, Chung, WK, Van Coster, R, Maertens, P, Noggle, SA, Henderson, CE & Wichterle, H 2015, 'Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin', Human Molecular Genetics, vol. 24, no. 5, pp. 1420-1431. https://doi.org/10.1093/hmg/ddu556
    Johnson-Kerner, Bethany L. ; Ahmad, Faizzan S. ; Diaz, Alejandro Garcia ; Greene, John Palmer ; Gray, Steven J. ; Samulski, Richard Jude ; Chung, Wendy K. ; Van Coster, Rudy ; Maertens, Paul ; Noggle, Scott A. ; Henderson, Christopher E. ; Wichterle, Hynek. / Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin. In: Human Molecular Genetics. 2015 ; Vol. 24, No. 5. pp. 1420-1431.
    @article{0a39bf5421264894b03f9e2db9fa3719,
    title = "Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin",
    abstract = "Giant axonal neuropathy (GAN) is a progressive neurodegenerative disease caused by autosomal recessive mutations in the GAN gene resulting in a loss of a ubiquitously expressed protein, gigaxonin. Gene replacement therapy is a promising strategy for treatment of the disease; however, the effectiveness and safety of gigaxonin reintroduction have not been tested in human GAN nerve cells. Herewe report the derivation of induced pluripotent stem cells (iPSCs) from three GAN patients with different GAN mutations. Motor neurons differentiated from GAN iPSCs exhibit accumulation of neurofilament (NF-L) and peripherin (PRPH) protein and formation of PRPH aggregates, the key pathological phenotypes observed in patients. Introduction of gigaxonin either using a lentiviral vector or as a stable transgene resulted in normalization of NEFL and PRPH levels in GAN neurons and disappearance of PRPH aggregates. Importantly, overexpression of gigaxonin had no adverse effect on survival of GAN neurons, supporting the feasibility of gene replacement therapy. Our findings demonstrate that GAN iPSCs provide a novel model for studying human GAN neuropathologies and for the development and testing of new therapies in relevant cell types.",
    author = "Johnson-Kerner, {Bethany L.} and Ahmad, {Faizzan S.} and Diaz, {Alejandro Garcia} and Greene, {John Palmer} and Gray, {Steven J.} and Samulski, {Richard Jude} and Chung, {Wendy K.} and {Van Coster}, Rudy and Paul Maertens and Noggle, {Scott A.} and Henderson, {Christopher E.} and Hynek Wichterle",
    year = "2015",
    month = "3",
    day = "1",
    doi = "10.1093/hmg/ddu556",
    language = "English",
    volume = "24",
    pages = "1420--1431",
    journal = "Human Molecular Genetics",
    issn = "0964-6906",
    publisher = "Oxford University Press",
    number = "5",

    }

    TY - JOUR

    T1 - Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin

    AU - Johnson-Kerner, Bethany L.

    AU - Ahmad, Faizzan S.

    AU - Diaz, Alejandro Garcia

    AU - Greene, John Palmer

    AU - Gray, Steven J.

    AU - Samulski, Richard Jude

    AU - Chung, Wendy K.

    AU - Van Coster, Rudy

    AU - Maertens, Paul

    AU - Noggle, Scott A.

    AU - Henderson, Christopher E.

    AU - Wichterle, Hynek

    PY - 2015/3/1

    Y1 - 2015/3/1

    N2 - Giant axonal neuropathy (GAN) is a progressive neurodegenerative disease caused by autosomal recessive mutations in the GAN gene resulting in a loss of a ubiquitously expressed protein, gigaxonin. Gene replacement therapy is a promising strategy for treatment of the disease; however, the effectiveness and safety of gigaxonin reintroduction have not been tested in human GAN nerve cells. Herewe report the derivation of induced pluripotent stem cells (iPSCs) from three GAN patients with different GAN mutations. Motor neurons differentiated from GAN iPSCs exhibit accumulation of neurofilament (NF-L) and peripherin (PRPH) protein and formation of PRPH aggregates, the key pathological phenotypes observed in patients. Introduction of gigaxonin either using a lentiviral vector or as a stable transgene resulted in normalization of NEFL and PRPH levels in GAN neurons and disappearance of PRPH aggregates. Importantly, overexpression of gigaxonin had no adverse effect on survival of GAN neurons, supporting the feasibility of gene replacement therapy. Our findings demonstrate that GAN iPSCs provide a novel model for studying human GAN neuropathologies and for the development and testing of new therapies in relevant cell types.

    AB - Giant axonal neuropathy (GAN) is a progressive neurodegenerative disease caused by autosomal recessive mutations in the GAN gene resulting in a loss of a ubiquitously expressed protein, gigaxonin. Gene replacement therapy is a promising strategy for treatment of the disease; however, the effectiveness and safety of gigaxonin reintroduction have not been tested in human GAN nerve cells. Herewe report the derivation of induced pluripotent stem cells (iPSCs) from three GAN patients with different GAN mutations. Motor neurons differentiated from GAN iPSCs exhibit accumulation of neurofilament (NF-L) and peripherin (PRPH) protein and formation of PRPH aggregates, the key pathological phenotypes observed in patients. Introduction of gigaxonin either using a lentiviral vector or as a stable transgene resulted in normalization of NEFL and PRPH levels in GAN neurons and disappearance of PRPH aggregates. Importantly, overexpression of gigaxonin had no adverse effect on survival of GAN neurons, supporting the feasibility of gene replacement therapy. Our findings demonstrate that GAN iPSCs provide a novel model for studying human GAN neuropathologies and for the development and testing of new therapies in relevant cell types.

    UR - http://www.scopus.com/inward/record.url?scp=84924440715&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84924440715&partnerID=8YFLogxK

    U2 - 10.1093/hmg/ddu556

    DO - 10.1093/hmg/ddu556

    M3 - Article

    VL - 24

    SP - 1420

    EP - 1431

    JO - Human Molecular Genetics

    JF - Human Molecular Genetics

    SN - 0964-6906

    IS - 5

    ER -